0001104659-23-111088.txt : 20231024 0001104659-23-111088.hdr.sgml : 20231024 20231024160528 ACCESSION NUMBER: 0001104659-23-111088 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231024 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231024 DATE AS OF CHANGE: 20231024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Milestone Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001408443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38899 FILM NUMBER: 231342745 BUSINESS ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 BUSINESS PHONE: (514) 336-0444 MAIL ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 8-K 1 tm2329058d1_8k.htm FORM 8-K
0001408443 false A8 00-0000000 QC 0001408443 2023-10-24 2023-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

October 24, 2023

 

 

 

MILESTONE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Québec   001-38899   Not applicable
(state or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

1111 Dr. Frederik-Philips Boulevard,    
Suite 420    
Montréal, Québec CA   H4M 2X6
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (514) 336-0444

 

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Shares   MIST   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On October 24, 2023, Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) issued a press release announcing the submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (the “FDA”) for etripamil for the treatment of paroxysmal supraventricular tachycardia (“PSVT”). A copy of the press release is attached hereto as Exhibit 99.1.

 

The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on its website in the “Investors & Media” section. Accordingly, investors should monitor such portions of its website, in addition to following press releases, filings with the U.S. Securities Exchange Commission (the “SEC”) and public conference calls and webcasts.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 8.01. Other Events.

 

On October 24, 2023, the Company announced the submission of an NDA to the FDA for etripamil for the treatment of PSVT, which follows the primary analysis and supportive assessments from the pivotal RAPID Phase 3 clinical trial that were recently published in The Lancet. PSVT is a condition characterized by an abnormality in the electrical system of the heart causing patients to have unexpected, often severely symptomatic episodes of rapid heart rate.

 

The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing, after which the FDA will notify the Company. The Company continues to advance commercial preparations to support the anticipated launch of etripamil with the proposed trade name, CARDAMYST™. The brand name has been conditionally approved by the FDA.

 

Forward-Looking Statements

 

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the timing of the anticipated launch of etripamil; the success of the NDA submission for etripamil nasal spray and the timing of the FDA’s approval of the NDA; and the FDA’s final approval of etripamil’s proposed trade name. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation and Russian hostilities in Ukraine and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the SEC, including in its annual report on Form 10-K for the year ended December 31, 2022, under the caption “Risk Factors,” as such discussion may be updated from time to time by subsequent filings, we may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

 

 

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No. Description
99.1 Press release, dated October 24, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MILESTONE PHARMACEUTICALS INC.
   
Date: October 24, 2023 By: /s/ Amit Hasija
    Amit Hasija
    Chief Financial Officer Principal Financial Officer

 

 

 

 

 EX-99.1 2 tm2329058d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

 

·Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT

 

·Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil, is twice as effective and three times as fast as a placebo in restoring normal heart rhythm for patients suffering from PSVT

 

·CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable and at-the-ready option in the treatment of serious heart arrhythmias

 

Montreal and Charlotte, N.C., October 24, 2023 -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). PVST is a condition characterized by an abnormality in the electrical system of the heart causing patients to have unexpected, often severely symptomatic episodes of rapid heart rate.

 

Representing the largest data package ever studied in PSVT, the Company believes the clinical trial program demonstrates that etripamil provided superior time to conversion to normal heart rhythm compared to placebo. The primary analysis and supportive assessments from the pivotal RAPID Phase 3 clinical trial were recently published in The Lancet.

 

“With the achievement of our first NDA submission, we want to thank the investigators, clinical trial teams, our colleagues and, most importantly, patients whose contributions were critical to completing our registration trials,” said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals. “With this submission, we are one step closer to getting etripamil into the hands of patients who are seeking a new treatment option that will allow them to take an active role in managing their PSVT.”

 

The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review. If accepted, Milestone Pharmaceuticals expects a standard review of 10 months of the company’s NDA. Milestone continues to advance commercial preparations to support the anticipated launch of etripamil with the proposed trade name, CARDAMYST™. The brand name is conditionally approved by the FDA.

 

About Pivotal RAPID Phase 3 Trial

 

Recently published in The Lancet, RAPID is a global, randomized, double-blind phase 3 clinical trial of etripamil versus placebo in patients with PSVT. The trial was designed to evaluate the safety and efficacy of self-administered etripamil for treating PSVT. The RAPID trial achieved its primary endpoint with 64% of patients who self-administered etripamil converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared to 31% on placebo (HR = 2.62, p<0.001). At one hour, the benefit was demonstrated in 73% of patients. In addition, significant reductions in time to conversion in patients who took etripamil were evident early and durable, with a median time to conversion of 17 minutes (95% CI: 13.4, 26.5) for patients treated with etripamil versus 54 minutes (95% CI: 38.7, 87.3) for patients treated with placebo. Data demonstrated statistically significant improvement in multiple defined symptoms of PSVT in patients receiving etripamil compared to placebo, using a patient-reported outcome (PRO) questionnaire. The safety and tolerability profile of etripamil is supportive of the NDA submission.

 

 

 

 

About Paroxysmal Supraventricular Tachycardia (PSVT)

 

An estimated 2 million people in the United States are currently diagnosed with PSVT which is a type of arrhythmia or abnormal heart rhythm. PSVT is characterized by episodes of rapid heartbeats often exceeding 150 to 200 beats per minute. Key features of PSVT include the sudden occurrence of episodes and very rapid heart rate. The heart rate can spike unpredictably and rapidly during an episode. The rapid heart rate often causes severe palpitations, shortness of breath, chest discomfort, dizziness, or lightheadedness, and distress, forcing patients to limit their daily activities. The uncertainty of when an episode of PSVT will strike or how long it will persist can provoke anxiety in patients and negatively impact their day-to-day life between episodes. The impact and morbidity from an attack can be especially detrimental in patients with underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary disease, or dehydration. Many doctors are dissatisfied with the lack of effective treatment options in addition to a prolonged, burdensome, and costly trip to the emergency department or, for some patients, an invasive ablation procedure.

 

About Etripamil

 

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray being developed for elevated and often highly symptomatic heart-rate attacks associated with PSVT and atrial fibrillation with a rapid ventricular rate (AFib-RVR). It is designed to be a rapid-response therapy that is self-administered by the patient, without the need for direct medical oversight. If approved, etripamil is intended to provide health care providers with a new treatment option to enable virtual care and patient self-management. If approved, the portable treatment, studied as self-administered, may provide patients with active management and a greater sense of control over their condition. Etripamil, proposed brand name CARDAMYST™, is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT and soon-to-be-reported Phase 2 proof-of-concept trial for the treatment of patients with AFib-RVR.

 

About Milestone Pharmaceuticals

 

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of PSVT and is in a Phase 2 proof-of-concept trial for the treatment of patients with AFib-RVR. The AFib-RVR study, ReVeRA, was selected for a Featured Science presentation at the American Heart Association (AHA) Scientific Sessions 2023. Milestone Pharmaceuticals operates in Canada and the United States. Find out more at www.milestonepharma.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could," "demonstrate," "designed," "develop," "estimate," "expect," "may," "pending," "plan," "potential," "progress," "will" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential of etripamil nasal spray to be the first rapid, reliable, safe, and at-the-ready option in the treatment of serious heart arrhythmias; the continued ability of etripamil provided superior time to conversion to normal heart rhythm compared to placebo; the timing of the anticipated launch of etripamil; the success of the NDA submission for etripamil nasal spray and the timing of the FDA’s approval of the NDA; the FDA’s final approval of etripamil’s proposed trade name; and the status and timing of the Phase 2 proof-of-concept trial of etripamil for the treatment of patients with AFib-RVR. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation and Russian hostilities in Ukraine and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2022, under the caption "Risk Factors," as such discussion may be updated from time to time by subsequent filings, we may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Contact:

 

Kim Fox, Vice President, Communications

 

kfox@milestonepharma.com

 

704-803-9295

 

 

 

 EX-101.SCH 3 mist-20231024.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mist-20231024_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mist-20231024_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2329058d1_ex99-1img004.jpg GRAPHIC begin 644 tm2329058d1_ex99-1img004.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 24, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 24, 2023
Entity File Number 001-38899
Entity Registrant Name MILESTONE PHARMACEUTICALS INC.
Entity Central Index Key 0001408443
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code A8
Entity Address, Address Line One 1111 Dr. Frederik-Philips Boulevard
Entity Address, Address Line Two Suite 420
Entity Address, City or Town Montréal
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H4M 2X6
City Area Code 514
Local Phone Number 336-0444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares
Trading Symbol MIST
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2329058d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001408443 2023-10-24 2023-10-24 iso4217:USD shares iso4217:USD shares 0001408443 false A8 00-0000000 QC 8-K 2023-10-24 MILESTONE PHARMACEUTICALS INC. 001-38899 1111 Dr. Frederik-Philips Boulevard Suite 420 Montréal CA H4M 2X6 514 336-0444 false false false false Common Shares MIST NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://milestonepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports mist-20231024.xsd mist-20231024_lab.xml mist-20231024_pre.xml tm2329058d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329058d1_8k.htm": { "nsprefix": "mist", "nsuri": "http://milestonepharma.com/20231024", "dts": { "schema": { "local": [ "mist-20231024.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mist-20231024_lab.xml" ] }, "presentationLink": { "local": [ "mist-20231024_pre.xml" ] }, "inline": { "local": [ "tm2329058d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://milestonepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329058d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329058d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-23-111088-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-111088-xbrl.zip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end